RxDoctor Payments Data

Elaine Heine, PA

Physician Assistant · Albuquerque, NMNPI 1932534229

Payments from drug & device makers

$1,374in general payments, 2019–2025

Across 41 payments — averaging $33.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$582
  • Gilead$507
  • Teva Pharmaceuticals USA, Inc.$86
  • Janssen Products, LP$85
  • Theratechnologies Inc.$58
  • Johnson & Johnson$41
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$1,28994%
  • Education$856%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,374 in reported general payments places this provider in the 80th percentile of 635 physician assistant providers in New Mexico.

See all physician assistant providers in New Mexico

Medicare billing

Part B allowed, 2024
$22,863
Medicare patients
54
Services billed
1,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala221$846,671
TivicayDolutegravir Sodium103$217,243
DescovyEmtricitabine/Tenofov Alafenam84$174,658
PrezcobixDarunavir/Cobicistat47$108,688
TriumeqAbacavir/Dolutegravir/Lamivudi27$96,293
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf20$91,849
GenvoyaElviteg/Cob/Emtri/Tenof Alafen14$53,552
MounjaroTirzepatide22$19,082
Maraviroc12$14,812
JardianceEmpagliflozin18$10,044
Atrovent HfaIpratropium Bromide15$6,820
Arnuity ElliptaFluticasone Furoate24$6,153
MyrbetriqMirabegron12$5,432
QnaslBeclomethasone Dipropionate13$3,721
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)32$3,707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$507$1,074,880319 claims
Viiv Healthcare CompanyTivicay, Triumeq$582$313,537130 claims
Johnson & JohnsonPrezcobix$41$108,68847 claims
Janssen Products, LPSymtuza$85$91,84920 claims
Teva Pharmaceuticals USA, Inc.Qnasl$86$3,72113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 635 physician assistant providers in New Mexico.

Other physician assistant in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →